UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 001-12465

 

 

 

CELL THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

501 Elliott Avenue West, Suite 400

Seattle, WA 98119

(206) 282-7100

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

PREFERRED STOCK PURCHASE RIGHTS

(Title of each class of securities covered by this Form)

 

 

COMMON STOCK, NO PAR VALUE

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)(i)		x		Rule 12h-3(b)(1)(i)		x
Rule 12g-4(a)(1)(ii)		¨		Rule 12h-3(b)(1)(ii)		¨
Rule 12g-4(a)(2)(i)		¨		Rule 12h-3(b)(2)(i)		¨
Rule 12g-4(a)(2)(ii)		¨		Rule 12h-3(b)(2)(ii)		¨
				Rule 15d-6		¨

Approximate number of holders of record as of the certification or notice date: 0

Pursuant to the requirements of the Securities Exchange Act of 1934, Cell Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

DATE:		April 4, 2007		BY:		/s/ Louis A. Bianco
						Louis A. Bianco
						Executive Vice President, Finance and Administration